参考文献/References:
[1] Chua KJ,Kwok WC,Aggarwal N,et al. Designer probiotics for the prevention and treatment of human diseases[J].Curr Opin Chem Biol,2017,40:8-16.DOI:10.1016/j.cbpa.2017.04.011.
[2] Bober JR,Beisel CL,Nair NU.Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications[J].Annu Rev Biomed Eng,2018,20:277-300.DOI:10.1146/annurev-bioeng-062117-121019.
[3] Li X,Fu GF,Fan YR,et al.Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy:selective inhibitor of angiogenesis and hypoxic tumor growth[J].Cancer Gene Ther,2003,10(2):105-111.DOI:10.1038/sj.cgt.7700530.
[4] Piñero-Lambea C,Ruano-Gallego D,Fernández LÁ.Engineered bacteria as therapeutic agents.Curr Opin Biotechnol[J].2015,35:94-102.DOI:10.1016/j.copbio.2015.05.004.
[5] Herold KC,Bundy BN,Long SA,et al.An Anti-CD3 antibody,teplizumab,in relatives at risk for type 1 diabetes[J].N Engl J Med,2019,381(7):603-613.DOI:10.1056/NEJMoa1902226.
[6] Takiishi T,Korf H,Van Belle TL,et al.Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice[J].J Clin Invest,2012,122(5):1717-1725.DOI:10.1172/JCI60530.
[7] Robert S,Gysemans C,Takiishi T,et al.Oral delivery of glutamic acid decarboxylase(GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice[J].Diabetes,2014,63(8):2876-2887.DOI:10.2337/db13-1236.
[8] Duan FF,Liu JH,March JC.Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes[J].Diabetes,2015,64(5):1794-1803.DOI:10.2337/db14-0635.
[9] Holmes D.Diabetes.Genetically engineered Lactobacilli reprogram intestinal cells to secrete insulin and ameliorate hyperglycaemia[J].Nat Rev Endocrinol,2015,11(4):192.DOI:10.1038/nrendo.2015.45.
[10] Agarwal P,Khatri P,Billack B,et al.Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis[J].Pharm Res,2014,31(12):3404-3414.DOI:10.1007/s11095-014-1430-3.
[11] Gillum MP,Zhang D,Zhang XM,et al.N-acylphosphatidylethanolamine,a gut-derived circulating factor induced by fat ingestion,inhibits food intake[J].Cell,2008,135(5):813-824.DOI:10.1016/j.cell.2008.10.043.
[12] Chen Z,Guo L,Zhang Y,et al.Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity[J].J Clin Invest,2014,124(8):3391-3406.DOI:10.1172/JCI72517.
[13] Ryan PM,Patterson E,Kent RM,et al.Recombinant incretin-secreting microbe improves metabolic dysfunction in high-fat diet fed rodents[J].Sci Rep,2017,7(1):13523.DOI:10.1038/s41598-017-14010-x.
[14] Singh AK,Pandey SK,Naresh Kumar G.Pyrroloquinoline quinone-secreting probiotic Escherichia coli Nissle 1917 ameliorates ethanol-induced oxidative damage and hyperlipidemia in rats[J].Alcohol Clin Exp Res,2014,38(7):2127-2137.DOI:10.1111/acer.12456.
[15] Somabhai CA,Raghuvanshi R,Nareshkumar G.Genetically engineered escherichia coli nissle 1917 synbiotics reduce metabolic effects induced by chronic consumption of dietary fructose[J].PLoS ONE,2016,11(10):e0164860.DOI:10.1371/journal.pone.0164860.
[16] Cai L,Li Q,Deng Y,et al.Construction and expression of recombinant uricaseexpressing genetically engineered bacteria and its application in rat model of hyperuricemia[J].Int J Mol Med,2020,45(5):1488-1500.DOI:10.3892/ijmm.2020.4512.
[17] Sarkissian CN,Shao Z,Blain F,et al.A different approach to treatment of phenylketonuria:phenylalanine degradation with recombinant phenylalanine ammonia lyase[J].Proc Natl Acad Sci U S A.1999,96(5):2339-2944.DOI:10.1073/pnas.96.5.2339.
[18] Shen TC,Albenberg L,Bittinger K,et al.Engineering the gut microbiota to treat hyperammonemia[J].J Clin Invest,2015,125(7):2841-2850.DOI:10.1172/JCI79214.
[19] Kurtz CB,Millet YA,Puurunen MK,et al.An engineered E.coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans[J].Sci Transl Med,2019,11(475):eaau7975.DOI:10.1126/scitranslmed.aau7975.
[20] Durrer KE,Allen MS,Hunt von Herbing I.Genetically engineered probiotic for the treatment of phenylketonuria(PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU[J].PLoS One,2017,12(5):e0176286.DOI:10.1371/journal.pone.0176286.
[21] Isabella VM,Ha BN,Castillo MJ,et al.Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria[J].Nat Biotechnol,2018,36(9):857-864.DOI:10.1038/nbt.4222.
[22] Crook N,Ferreiro A,Gasparrini AJ,et al.Adaptive strategies of the candidate probiotic E.coli nissle in the mammalian gut[J].Cell Host Microbe,2019,25(4):499-512.DOI:10.1016/j.chom.2019.02.005.
[23] Puurunen MK,Vockley J,Searle SL,et al.Safety and pharmacodynamics of an engineered E.coli Nissle for the treatment of phenylketonuria:a first-in-human phase 1/2a study[J].Nat Metab,2021,3(8):1125-1132.DOI:10.1038/s42255-021-00430-7.
[24] Wright O,Delmans M,Stan GB,et al.GeneGuard:a modular plasmid system designed for biosafety[J].ACS Synth Biol,2015,4(3):307-316.DOI:10.1021/sb500234s.
[25] Mandell DJ,Lajoie MJ,Mee MT,et al.Biocontainment of genetically modified organisms by synthetic protein design[J].Nature,2015,518(7537):55-60.DOI:10.1038/nature14121.
[26] Charbonneau MR,Isabella VM,Li N,et al.Developing a new class of engineered live bacterial therapeutics to treat human diseases[J].Nat Commun,2020,11(1):1738.DOI:10.1038/s41467-020-15508-1.
相似文献/References:
[1]艾华,谢岚.Irisin与代谢性疾病的关系[J].国际内分泌代谢杂志,2014,(05):316.[doi:10.3760/cma.j.issn.1673-4157.2014.05.008]
Ai Hua,Xie Lan.Relationship between irisin and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(01):316.[doi:10.3760/cma.j.issn.1673-4157.2014.05.008]
[2]陈恺情,卜瑞芳.Irisin——可否让代谢性疾病治疗进入新时代[J].国际内分泌代谢杂志,2016,36(01):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
Chen Kaiqing,Bu Ruifang..Could irisin lead the treatment of metabolic diseases into a new era?[J].International Journal of Endocrinology and Metabolism,2016,36(01):38.[doi:10.3760/cma.j.issn.1673-4157.2016.01.009]
[3]谢绍锋,黄莉吉,王昆,等.南京市城区40岁以上人群超重、肥胖流行
特点调查分析[J].国际内分泌代谢杂志,2016,36(03):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
Xie Shaofeng*,Huang Liji,Wang Kun,et al.Epidemiological investigation of overweight and obesity in population aged 40 years or older in Nanjing City[J].International Journal of Endocrinology and Metabolism,2016,36(01):145.[doi:10.3760/cma.j.issn.1673-4157.2016.03.01]
[4]祝凌妃,杨震,秦利.肌肉因子与代谢性疾病[J].国际内分泌代谢杂志,2016,36(05):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
Zhu Lingfei,Yang Zhen,Qin li.Myokines and metabolic disease[J].International Journal of Endocrinology and Metabolism,2016,36(01):355.[doi:10.3760/cma.j.issn.1673-4157.2016.05.19]
[5]项芬芬,张学梅,高英慧,等.p53与物质能量代谢的关系[J].国际内分泌代谢杂志,2017,37(04):262.
Xiang Fenfen*,Zhang Xuemei,Gao Yinghui,et al.Relationship between p53 and material, energy metabolism[J].International Journal of Endocrinology and Metabolism,2017,37(01):262.
[6]杨雪 相萍萍 陈国芳 刘超.IGF-1在代谢性疾病中的作用[J].国际内分泌代谢杂志,2018,38(01):33.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
Yang Xue,Xiang Pingping,Chen Guofang,et al.Effects of IGF-1 in metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(01):33.[doi:10.3760/cma.j.issn.1673-4157.2018.01.009]
[7]杨雪 韦晓 杨婉薇 陈国芳 刘超.代谢组学在糖尿病研究中的应用[J].国际内分泌代谢杂志,2018,38(05):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
Yang Xue,Wei Xiao,Yang Wanwei,et al.Application of metabonomics in diabetic research[J].International Journal of Endocrinology and Metabolism,2018,38(01):343.[doi:10.3760/cma.j.issn.1673-4157.2018.05.015]
[8]王佳蓓 陈风 刘莹 王涤非.Nur77与物质能量代谢的关系[J].国际内分泌代谢杂志,2019,39(01):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
Wang Jiabei,Chen Feng,Liu Ying,et al.Relationship between Nur77 and meterial, energy metabolism[J].International Journal of Endocrinology and Metabolism,2019,39(01):49.[doi:10.3760/cma.j.issn.1673-4157.2019.01.012]
[9]王雪 朱惠娟 龚凤英.棕色脂肪因子与代谢性疾病[J].国际内分泌代谢杂志,2019,39(06):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
Wang Xue,Zhu Huijuan,Gong Fengying.Relationship between brown adipocytokine and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2019,39(01):409.[doi:10.3760/cma.j.issn.1673-4157.2019.06.012]
[10]王鹏程,姜长涛.肠源神经酰胺与代谢性疾病[J].国际内分泌代谢杂志,2021,41(04):295.[doi:10.3760/cma.j.cn121383-20200610-06029]
Wang Pengcheng,Jiang Changtao..Relationship between intestinal ceramide and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2021,41(01):295.[doi:10.3760/cma.j.cn121383-20200610-06029]